DK2091949T3 - Indolderivater som S1P1-receptor agonister - Google Patents

Indolderivater som S1P1-receptor agonister

Info

Publication number
DK2091949T3
DK2091949T3 DK07857808.5T DK07857808T DK2091949T3 DK 2091949 T3 DK2091949 T3 DK 2091949T3 DK 07857808 T DK07857808 T DK 07857808T DK 2091949 T3 DK2091949 T3 DK 2091949T3
Authority
DK
Denmark
Prior art keywords
receptor agonists
indole derivatives
indole
derivatives
agonists
Prior art date
Application number
DK07857808.5T
Other languages
English (en)
Inventor
Mahmood Ahmed
James Myatt
David Norton
Dean Andrew Rivers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2091949(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0625647A external-priority patent/GB0625647D0/en
Priority claimed from GB0707615A external-priority patent/GB0707615D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK2091949T3 publication Critical patent/DK2091949T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
DK07857808.5T 2006-12-21 2007-12-19 Indolderivater som S1P1-receptor agonister DK2091949T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625647A GB0625647D0 (en) 2006-12-21 2006-12-21 Compounds
GB0707615A GB0707615D0 (en) 2007-04-19 2007-04-19 Compounds
PCT/EP2007/064185 WO2008074821A1 (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists

Publications (1)

Publication Number Publication Date
DK2091949T3 true DK2091949T3 (da) 2011-07-18

Family

ID=39283563

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10158582.6T DK2206710T3 (da) 2006-12-21 2007-12-19 Indolderivater som s1p1-receptor agonister
DK07857808.5T DK2091949T3 (da) 2006-12-21 2007-12-19 Indolderivater som S1P1-receptor agonister

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10158582.6T DK2206710T3 (da) 2006-12-21 2007-12-19 Indolderivater som s1p1-receptor agonister

Country Status (32)

Country Link
US (1) US8101775B2 (da)
EP (2) EP2091949B1 (da)
JP (1) JP5309034B2 (da)
KR (1) KR101495927B1 (da)
CN (1) CN103012390B (da)
AR (1) AR064452A1 (da)
AT (1) ATE509927T1 (da)
AU (1) AU2007336224B2 (da)
BR (1) BRPI0721127A2 (da)
CA (1) CA2673468C (da)
CL (1) CL2007003755A1 (da)
CR (2) CR10922A (da)
CY (2) CY1111702T1 (da)
DK (2) DK2206710T3 (da)
DO (1) DOP2009000133A (da)
EA (1) EA017406B1 (da)
ES (1) ES2389879T3 (da)
HR (2) HRP20110456T1 (da)
IL (1) IL199187A (da)
JO (1) JO2701B1 (da)
MA (1) MA30999B1 (da)
MX (1) MX2009006882A (da)
MY (2) MY156822A (da)
NO (1) NO20092385L (da)
NZ (1) NZ577387A (da)
PE (2) PE20081398A1 (da)
PL (2) PL2091949T3 (da)
PT (2) PT2206710E (da)
SG (1) SG177914A1 (da)
SI (2) SI2206710T1 (da)
TW (1) TWI393564B (da)
WO (1) WO2008074821A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012738A (es) 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
CL2008001099A1 (es) * 2007-04-19 2008-10-24 Glaxo Group Ltd Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
HUE025984T2 (hu) 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
WO2009151626A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
US8217028B2 (en) 2008-06-20 2012-07-10 Glaxo Group Limited 1,2,4-oxadiazole indole compounds
DK2307007T3 (da) * 2008-07-23 2014-11-10 Novartis Ag Sphingosin-1-phosphat-receptormodulatorer samt deres anvendelse til behandling af muskelinflammation
HRP20161133T1 (hr) 2008-07-23 2016-12-02 Arena Pharmaceuticals, Inc. DERIVATI SUSPSTITUIRANE 1,2,3,4-TETRAHIDROCIKLOPENTA[b]INDOL-3-IL-OCTENE KISELINE KORISNI U LIJEČENJU AUTOIMUNIH I UPALNIH POREMEĆAJA
CN105816453B (zh) * 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
CA2743397C (en) 2008-12-18 2017-02-28 Mathilde Muzerelle Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
SI2498610T2 (sl) 2009-11-13 2024-10-30 Receptos Llc Selektivni modulatorji receptorja sfingozin-1-fosfata in postopki kiralne sinteze
WO2011072488A1 (en) * 2009-12-18 2011-06-23 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN105503882B (zh) * 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
ES2548683T3 (es) 2010-04-23 2015-10-20 Bristol-Myers Squibb Company Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
PT2672823T (pt) 2011-02-07 2016-11-21 Biogen Ma Inc Agentes que modulam s1p
WO2012158550A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
EP3492465B1 (en) * 2016-07-22 2021-03-24 Shijiazhuang Sagacity New Drug Development Co., Ltd. S1p1 agonist and application thereof
EP3518922B1 (en) * 2016-09-29 2026-02-11 Receptos LLC Compounds and methods for treating lupus
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
TW202131921A (zh) 2019-10-31 2021-09-01 瑞士商愛杜西亞製藥有限公司 Cxcr7拮抗劑與s1p1受體調節劑之組合
WO2021112461A1 (ko) 2019-12-03 2021-06-10 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물
US12604895B2 (en) 2020-02-11 2026-04-21 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de) 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
CA2524867A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
CN1859908A (zh) 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
JP2008517915A (ja) 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環
JP5024039B2 (ja) 2005-02-25 2012-09-12 小野薬品工業株式会社 インドール化合物およびその用途
BRPI0609668A2 (pt) 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
JP2008545767A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
JP2009506046A (ja) 2005-08-23 2009-02-12 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制剤化合物および組成物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
MX2008012738A (es) * 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
CL2007002593A1 (es) 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
CL2008001099A1 (es) 2007-04-19 2008-10-24 Glaxo Group Ltd Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.

Also Published As

Publication number Publication date
EP2206710A1 (en) 2010-07-14
PT2206710E (pt) 2012-09-10
WO2008074821A1 (en) 2008-06-26
KR101495927B1 (ko) 2015-02-25
PE20081398A1 (es) 2008-11-19
PE20121076A1 (es) 2012-09-05
SG177914A1 (en) 2012-02-28
CN103012390A (zh) 2013-04-03
AU2007336224B2 (en) 2013-01-10
EA017406B1 (ru) 2012-12-28
HRP20120685T1 (hr) 2012-09-30
AR064452A1 (es) 2009-04-01
EP2091949B1 (en) 2011-05-18
NO20092385L (no) 2009-08-24
MY156822A (en) 2016-03-31
NZ577387A (en) 2012-01-12
HK1130255A1 (en) 2009-12-24
SI2206710T1 (sl) 2012-10-30
CY1111702T1 (el) 2015-10-07
PL2206710T3 (pl) 2012-11-30
CA2673468A1 (en) 2008-06-26
HK1140761A1 (en) 2010-10-22
ES2389879T3 (es) 2012-11-02
MY148470A (en) 2013-04-30
TWI393564B (zh) 2013-04-21
US20100113796A1 (en) 2010-05-06
AU2007336224A1 (en) 2008-06-26
TW200843736A (en) 2008-11-16
HRP20110456T1 (hr) 2011-07-31
JP5309034B2 (ja) 2013-10-09
CY1113131T1 (el) 2016-04-13
EP2206710B1 (en) 2012-07-04
CA2673468C (en) 2015-06-02
CN103012390B (zh) 2015-08-26
BRPI0721127A2 (pt) 2014-03-11
IL199187A0 (en) 2010-03-28
DK2206710T3 (da) 2012-08-27
PT2091949E (pt) 2011-07-13
CR20140316A (es) 2014-08-20
EP2091949A1 (en) 2009-08-26
JP2010513397A (ja) 2010-04-30
MX2009006882A (es) 2009-07-03
PL2091949T3 (pl) 2011-10-31
SI2091949T1 (sl) 2011-08-31
CR10922A (es) 2009-08-12
ATE509927T1 (de) 2011-06-15
DOP2009000133A (es) 2009-08-15
EA200970612A1 (ru) 2009-10-30
IL199187A (en) 2015-04-30
JO2701B1 (en) 2013-03-03
KR20090092290A (ko) 2009-08-31
MA30999B1 (fr) 2009-12-01
CL2007003755A1 (es) 2008-08-22
US8101775B2 (en) 2012-01-24

Similar Documents

Publication Publication Date Title
DK2206710T3 (da) Indolderivater som s1p1-receptor agonister
DK2069322T3 (da) THIOPHENDERIVATER SOM S1P1/EDG1-receptoragonister
DK2125797T3 (da) Aminopyridinderivater som s1p1/edg1-receptoragonister
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
DK1856110T3 (da) Oxyindol derivater som 5HT4-receptor agonister
DK2029549T3 (da) Phenyl-pyrazol-derivater som ikke-steroide glucocoricoid-receptorligander
IL192657A (en) Theophenic history as 1edg / 1p1s receptor agonists
DK1989196T3 (da) Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
BRPI0715324A2 (pt) Composto de indol
DK2094658T3 (da) Tetrahydrocyclopenta[B]indolforbindelser som androgenreceptormodulatorer
DK2225231T3 (da) Aminotriazolderivater som alx-agonister
DK2195311T3 (da) Pyridinderivater som S1P1/EDG1-receptormodulatorer
DK2066669T3 (da) Adenosinderivater som A2A-receptoragonister
DK2144897T3 (da) 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
IL198931A0 (en) Benzamide derivatives as ep4 receptor agonists
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
DK2046802T3 (da) 2-substituerede methylpenamderivater
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK2148873T3 (da) 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
DK2132185T3 (da) Pyrimidinyl-piperaziner nyttige som dopamin-D3/D2-receptorligander
DK1740583T3 (da) Oxadiazolon-derivater som ppar-delta-agonister